Sarah Auburn

Biographic Data

ID9066499
NAMESarah Auburn
GIVEN NAMESSarah
FAMILY NAMEAuburn
SIGNATUREAUBURN S
AFFILIATIONSCharles Darwin University
ORCID0000-0002-4638-536X
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS0
AUTHOR COUNT1
EDITOR COUNT5
FIRST PUBLICATION YEAR2022
LATEST PUBLICATION YEAR2024
H-INDEX0

  • Using a mobile nanopore sequencing lab for end-to-end genomic surveillance of Plasmodium falciparum

    Open AccessAurel Holzschuh, Anita Lerch et al.ARTICLEPLOS Global Public Health2024

    Genomic epidemiology holds promise for malaria control and elimination efforts, for example by informing on Plasmodium falciparum genetic diversity and prevalence of mutations conferring anti-malarial drug resistance. Limited sequencing infrastructure in many malaria-endemic areas prevents the rapid generation of genomic data. To address these issues, we developed and validated assays for P . falciparum nanopore sequencing in endemic sites using …

  • Increasing incidence of Plasmodium ovale and persistent reporting of Plasmodium vivax in imported malaria cases

    Open AccessXiaoxiao Wang, Wenjie Xu et al.ARTICLEFrontiers in Public Health2023

    Background This study aimed at exploring the epidemiological pattern of imported malaria in China before malaria elimination in 2021, to provide evidence-based data for preventing malaria re-establishment in China. Methods Nine-year surveillance data on imported malaria in four provincial-level administrative divisions (PLADs) (Anhui, Chongqing, Guangxi, and Zhejiang) between 2011 and 2019 were thoroughly collected and analyzed. Results A quite s…

  • Development and evaluation of PlasmoPod

    Open AccessPhilippe Bechtold, Philipp Wagner et al.ARTICLEPLOS Global Public Health2023

    Malaria surveillance is hampered by the widespread use of diagnostic tests with low sensitivity. Adequate molecular malaria diagnostics are often only available in centralized laboratories. PlasmoPod is a novel cartridge-based nucleic acid amplification test for rapid, sensitive, and quantitative detection of malaria parasites. PlasmoPod is based on reverse-transcription quantitative polymerase chain reaction (RT-qPCR) of the highly abundant Plas…

  • Clinical needs assessment to inform development of a new assay to detect antimalarial drugs in patient samples

    Open AccessErin S Coonahan, Chanaki Amaratunga et al.ARTICLEPLOS Global Public Health2023

    Point-of-care assays have greatly increased access to diagnostic information and improved healthcare outcomes globally, especially in the case of tropical diseases in rural settings. Increased recognition of the impact of these tools and increased funding, along with advances in technology have led to a surge in development of new assays. However, many new tools fail to fulfill their intended purpose due to a lack of clinical impact, operational …

  • What Africa can do to accelerate and sustain progress against malaria

    Open AccessFredros O Okumu, Margaret Gyapong et al.ARTICLEPLOS Global Public Health2022

    After a longstanding global presence, malaria is now largely non-existent or suppressed in most parts of the world. Today, cases and deaths are primarily concentrated in sub-Saharan Africa. According to many experts, this persistence on the African continent reflects factors such as resistance to insecticides and drugs as well as insufficient access to essential commodities such as insecticide-treated nets and effective drugs. Crucially, however,…

  • Performance of highly sensitive and conventional rapid diagnostic tests for clinical and subclinical Plasmodium falciparum infections, and hrp2/3 deletion status in Burundi

    Open AccessDavid Niyukuri, Denis Sinzinkayo et al.ARTICLEPLOS Global Public Health2022

    Rapid diagnostic tests (RDTs) are a key tool for the diagnosis of malaria infections among clinical and subclinical individuals. Low-density infections, and deletions of the P . falciparum hrp2 / 3 genes (encoding the HRP2 and HRP3 proteins detected by many RDTs) present challenges for RDT-based diagnosis. The novel Rapigen Biocredit three-band Plasmodium falciparum HRP2/LDH RDT was evaluated among 444 clinical and 468 subclinical individuals in …